...
The SAP specifies that planned collected visits, including baseline measurements, are to be used in analyses and displays of results. In fact, no Unscheduled Visits exist in the source data. If the planned physiology assessment is not done or invalid, the investigator may choose to use a previous or repeat assessment of that parameter as the value to be used at that visit for the scoring of APACHE II. The total score records for 1 subject were collected at 3 visits, plus a derived last observed value (LOV) endpoint record for the APACHE II. Visit 1 is remapped to AVISIT = "BASELINE".
Update the below dataset and title according to the current QRS Short_Name instrument.
APACHE II Complete Analysis Dataset
...
Dataset wrap |
---|
|
Dataset2 |
---|
Row | STUDYID | USUBJID | SITEID | RSSEQ | ASEQ | ITTFL | TRTP | PARAM | PARAMCD | PARAMN | PARCAT1 | VISIT | VISITNUM | AVISIT | AVISITN | RSDTC | ADT | ADY | RSORRES | RSORRESU | RSLOBXFL | RSCBRFL | AVAL | DTYPE | ABLFL | COUNTRY | REGION1 | REGION1N | 1 | STUDYX | X-100-P0001 | 100 | 1 | 1 | Y | DRUG A + SOC | APCH1-Temperature - Rectal | APCH101 | 1 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 38.5-38.9 | C | Y |
| 1 |
| Y | USA | North America | 1 | 2 | STUDYX | X-100-P0001 | 100 | 2 | 2 | Y | DRUG A + SOC | APCH1-Mean Arterial Pressure | APCH102 | 2 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 110-129 | mmHg | Y |
| 2 |
| Y | USA | North America | 1 | 3 | STUDYX | X-100-P0001 | 100 | 3 | 3 | Y | DRUG A + SOC | APCH1-Heart Rate | APCH103 | 3 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 70-109 | beats/min | Y |
| 0 |
| Y | USA | North America | 1 | 4 | STUDYX | X-100-P0001 | 100 | 4 | 4 | Y | DRUG A + SOC | APCH1-Respiratory Rate | APCH104 | 4 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 25-34 | breaths/min | Y |
| 1 |
| Y | USA | North America | 1 | 5 | STUDYX | X-100-P0001 | 100 | 5 | 5 | Y | DRUG A + SOC | APCH1-Oxygenation: A-aDO2 | APCH105A | 5 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 |
|
|
| Y |
|
|
| USA | North America | 1 | 6 | STUDYX | X-100-P0001 | 100 | 6 | 6 | Y | DRUG A + SOC | APCH1-Oxygenation: PaO2 | APCH105B | 6 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 61-70 | mmHg | Y |
| 1 |
| Y | USA | North America | 1 | 7 | STUDYX | X-100-P0001 | 100 | 7 | 7 | Y | DRUG A + SOC | APCH1-Arterial pH | APCH106A | 7 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 7.15-7.24 |
| Y |
| 3 |
| Y | USA | North America | 1 | 8 | STUDYX | X-100-P0001 | 100 | 8 | 8 | Y | DRUG A + SOC | APCH1-Serum HCO3 | APCH106B | 8 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 |
|
|
| Y |
|
|
| USA | North America | 1 | 9 | STUDYX | X-100-P0001 | 100 | 9 | 9 | Y | DRUG A + SOC | APCH1-Serum Sodium | APCH107 | 9 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 150-154 | mmol/L | Y |
| 1 |
| Y | USA | North America | 1 | 10 | STUDYX | X-100-P0001 | 100 | 10 | 10 | Y | DRUG A + SOC | APCH1-Serum Potassium | APCH108 | 10 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 3.5-5.4 | mmol/L | Y |
| 0 |
| Y | USA | North America | 1 | 11 | STUDYX | X-100-P0001 | 100 | 11 | 11 | Y | DRUG A + SOC | APCH1-Serum Creatinine | APCH109 | 11 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | <0.6 | mg/dL | Y |
| 2 |
| Y | USA | North America | 1 | 12 | STUDYX | X-100-P0001 | 100 | 12 | 12 | Y | DRUG A + SOC | APCH1-Hematocrit | APCH110 | 12 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 20-29.9 | % | Y |
| 2 |
| Y | USA | North America | 1 | 13 | STUDYX | X-100-P0001 | 100 | 13 | 13 | Y | DRUG A + SOC | APCH1-White Blood Count | APCH111 | 13 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 20-39.9 | 10^9/L | Y |
| 2 |
| Y | USA | North America | 1 | 14 | STUDYX | X-100-P0001 | 100 | 14 | 14 | Y | DRUG A + SOC | APCH1-15 Minus Glasgow Coma Score | APCH112 | 14 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 3 |
| Y |
| 3 |
| Y | USA | North America | 1 | 15 | STUDYX | X-100-P0001 | 100 | 15 | 15 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score | APCH113 | 15 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 18 |
| Y |
| 18 |
| Y | USA | North America | 1 | 16 | STUDYX | X-100-P0001 | 100 |
| 16 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score - Analysis | APCH1TPS | 16 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 |
|
| Y |
| 18 |
| Y | USA | North America | 1 | 17 | STUDYX | X-100-P0001 | 100 | 16 | 17 | Y | DRUG A + SOC | APCH1-B: Age Points | APCH114 | 17 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 45-54 | YEARS | Y |
| 2 |
| Y | USA | North America | 1 | 18 | STUDYX | X-100-P0001 | 100 | 17 | 18 | Y | DRUG A + SOC | APCH1-C: Chronic Health Points | APCH115 | 18 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | for elective postoperative patients |
| Y |
| 2 |
| Y | USA | North America | 1 | 19 | STUDYX | X-100-P0001 | 100 | 18 | 19 | Y | DRUG A + SOC | APCH1-Total APACHE II Score | APCH116 | 19 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 | 22 |
| Y |
| 22 |
| Y | USA | North America | 1 | 20 | STUDYX | X-100-P0001 | 100 |
| 20 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-06-24 | 24JUN2014 | -5 |
|
| Y |
| 22 |
| Y | USA | North America | 1 | 21 | STUDYX | X-100-P0001 | 100 | 19 | 21 | Y | DRUG A + SOC | APCH1-Temperature - Rectal | APCH101 | 1 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 38.5-38.9 | C |
|
| 1 |
|
| USA | North America | 1 | 22 | STUDYX | X-100-P0001 | 100 | 20 | 22 | Y | DRUG A + SOC | APCH1-Mean Arterial Pressure | APCH102 | 2 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 70–109 | mmHg |
|
| 0 |
|
| USA | North America | 1 | 23 | STUDYX | X-100-P0001 | 100 | 21 | 23 | Y | DRUG A + SOC | APCH1-Heart Rate | APCH103 | 3 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 70-109 | beats/min |
|
| 0 |
|
| USA | North America | 1 | 24 | STUDYX | X-100-P0001 | 100 | 22 | 24 | Y | DRUG A + SOC | APCH1-Respiratory Rate | APCH104 | 4 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 25-34 | breaths/min |
|
| 1 |
|
| USA | North America | 1 | 25 | STUDYX | X-100-P0001 | 100 | 23 | 25 | Y | DRUG A + SOC | APCH1-Oxygenation: A-aDO2 | APCH105A | 5 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 |
|
|
| Y |
|
|
| USA | North America | 1 | 26 | STUDYX | X-100-P0001 | 100 | 24 | 26 | Y | DRUG A + SOC | APCH1-Oxygenation: PaO2 | APCH105B | 6 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 61-70 | mmHg |
|
| 1 |
|
| USA | North America | 1 | 27 | STUDYX | X-100-P0001 | 100 | 25 | 27 | Y | DRUG A + SOC | APCH1-Arterial pH | APCH106A | 7 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 7.25-7.32 |
|
|
| 2 |
|
| USA | North America | 1 | 28 | STUDYX | X-100-P0001 | 100 | 26 | 28 | Y | DRUG A + SOC | APCH1-Serum HCO3 | APCH106B | 8 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 |
|
|
| Y |
|
|
| USA | North America | 1 | 29 | STUDYX | X-100-P0001 | 100 | 27 | 29 | Y | DRUG A + SOC | APCH1-Serum Sodium | APCH107 | 9 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 150-154 | mmol/L |
|
| 1 |
|
| USA | North America | 1 | 30 | STUDYX | X-100-P0001 | 100 | 28 | 30 | Y | DRUG A + SOC | APCH1-Serum Potassium | APCH108 | 10 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 3.5-5.4 | mmol/L |
|
| 0 |
|
| USA | North America | 1 | 31 | STUDYX | X-100-P0001 | 100 | 29 | 31 | Y | DRUG A + SOC | APCH1-Serum Creatinine | APCH109 | 11 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 0.6-1.4 | mg/dL |
|
| 0 |
|
| USA | North America | 1 | 32 | STUDYX | X-100-P0001 | 100 | 30 | 32 | Y | DRUG A + SOC | APCH1-Hematocrit | APCH110 | 12 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 20-29.9 | % |
|
| 2 |
|
| USA | North America | 1 | 33 | STUDYX | X-100-P0001 | 100 | 31 | 33 | Y | DRUG A + SOC | APCH1-White Blood Count | APCH111 | 13 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 15-19.9 | 10^9/L |
|
| 1 |
|
| USA | North America | 1 | 34 | STUDYX | X-100-P0001 | 100 | 32 | 34 | Y | DRUG A + SOC | APCH1-15 Minus Glasgow Coma Score | APCH112 | 14 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 1 |
|
|
| 1 |
|
| USA | North America | 1 | 35 | STUDYX | X-100-P0001 | 100 | 33 | 35 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score | APCH113 | 15 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 10 |
|
|
| 10 |
|
| USA | North America | 1 | 36 | STUDYX | X-100-P0001 | 100 |
| 36 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score - Analysis | APCH1TPS | 16 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 |
|
|
|
| 10 |
|
| USA | North America | 1 | 37 | STUDYX | X-100-P0001 | 100 | 34 | 37 | Y | DRUG A + SOC | APCH1-B: Age Points | APCH114 | 17 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 45-54 | YEARS |
|
| 2 |
|
| USA | North America | 1 | 38 | STUDYX | X-100-P0001 | 100 | 35 | 38 | Y | DRUG A + SOC | APCH1-C: Chronic Health Points | APCH115 | 18 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | for elective postoperative patients |
|
|
| 2 |
|
| USA | North America | 1 | 39 | STUDYX | X-100-P0001 | 100 | 36 | 39 | Y | DRUG A + SOC | APCH1-Total APACHE II Score | APCH116 | 19 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 | 14 |
|
|
| 14 |
|
| USA | North America | 1 | 40 | STUDYX | X-100-P0001 | 100 |
| 40 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 2014-07-05 | 05JUL2014 | 7 |
|
|
|
| 14 |
|
| USA | North America | 1 | 41 | STUDYX | X-100-P0001 | 100 | 37 | 41 | Y | DRUG A + SOC | APCH1-Temperature - Rectal | APCH101 | 1 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 36-38.4 | C |
|
| 0 |
|
| USA | North America | 1 | 42 | STUDYX | X-100-P0001 | 100 | 38 | 42 | Y | DRUG A + SOC | APCH1-Mean Arterial Pressure | APCH102 | 2 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 70–109 | mmHg |
|
| 0 |
|
| USA | North America | 1 | 43 | STUDYX | X-100-P0001 | 100 | 39 | 43 | Y | DRUG A + SOC | APCH1-Heart Rate | APCH103 | 3 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 70-109 | beats/min |
|
| 0 |
|
| USA | North America | 1 | 44 | STUDYX | X-100-P0001 | 100 | 40 | 44 | Y | DRUG A + SOC | APCH1-Respiratory Rate | APCH104 | 4 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 12–24 | breaths/min |
|
| 0 |
|
| USA | North America | 1 | 45 | STUDYX | X-100-P0001 | 100 | 41 | 45 | Y | DRUG A + SOC | APCH1-Oxygenation: A-aDO2 | APCH105A | 5 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 |
|
|
| Y |
|
|
| USA | North America | 1 | 46 | STUDYX | X-100-P0001 | 100 | 42 | 46 | Y | DRUG A + SOC | APCH1-Oxygenation: PaO2 | APCH105B | 6 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 61-70 | mmHg |
|
| 1 |
|
| USA | North America | 1 | 47 | STUDYX | X-100-P0001 | 100 | 43 | 47 | Y | DRUG A + SOC | APCH1-Arterial pH | APCH106A | 7 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 7.33-7.49 |
|
|
| 0 |
|
| USA | North America | 1 | 48 | STUDYX | X-100-P0001 | 100 | 44 | 48 | Y | DRUG A + SOC | APCH1-Serum HCO3 | APCH106B | 8 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 |
|
|
| Y |
|
|
| USA | North America | 1 | 49 | STUDYX | X-100-P0001 | 100 | 45 | 49 | Y | DRUG A + SOC | APCH1-Serum Sodium | APCH107 | 9 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 130-149 | mmol/L |
|
| 0 |
|
| USA | North America | 1 | 50 | STUDYX | X-100-P0001 | 100 | 46 | 50 | Y | DRUG A + SOC | APCH1-Serum Potassium | APCH108 | 10 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 3.5-5.4 | mmol/L |
|
| 0 |
|
| USA | North America | 1 | 51 | STUDYX | X-100-P0001 | 100 | 47 | 51 | Y | DRUG A + SOC | APCH1-Serum Creatinine | APCH109 | 11 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 0.6-1.4 | mg/dL |
|
| 0 |
|
| USA | North America | 1 | 52 | STUDYX | X-100-P0001 | 100 | 48 | 52 | Y | DRUG A + SOC | APCH1-Hematocrit | APCH110 | 12 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 46-49.9 | % |
|
| 1 |
|
| USA | North America | 1 | 53 | STUDYX | X-100-P0001 | 100 | 49 | 53 | Y | DRUG A + SOC | APCH1-White Blood Count | APCH111 | 13 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 3-14.9 | 10^9/L |
|
| 0 |
|
| USA | North America | 1 | 54 | STUDYX | X-100-P0001 | 100 | 50 | 54 | Y | DRUG A + SOC | APCH1-15 Minus Glasgow Coma Score | APCH112 | 14 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 0 |
|
|
| 0 |
|
| USA | North America | 1 | 55 | STUDYX | X-100-P0001 | 100 | 51 | 55 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score | APCH113 | 15 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 2 |
|
|
| 2 |
|
| USA | North America | 1 | 56 | STUDYX | X-100-P0001 | 100 |
| 56 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score - Analysis | APCH1TPS | 16 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 |
|
|
|
| 2 |
|
| USA | North America | 1 | 57 | STUDYX | X-100-P0001 | 100 | 52 | 57 | Y | DRUG A + SOC | APCH1-B: Age Points | APCH114 | 17 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 45-54 | YEARS |
|
| 2 |
|
| USA | North America | 1 | 58 | STUDYX | X-100-P0001 | 100 | 53 | 58 | Y | DRUG A + SOC | APCH1-C: Chronic Health Points | APCH115 | 18 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | for elective postoperative patients |
|
|
| 2 |
|
| USA | North America | 1 | 59 | STUDYX | X-100-P0001 | 100 | 54 | 59 | Y | DRUG A + SOC | APCH1-Total APACHE II Score | APCH116 | 19 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 | 6 |
|
|
| 6 |
|
| USA | North America | 1 | 60 | STUDYX | X-100-P0001 | 100 |
| 60 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 2014-07-13 | 13JUL2014 | 15 |
|
|
|
| 6 |
|
| USA | North America | 1 | 61 | STUDYX | X-200-P0002 | 200 | 1 | 1 | Y | SOC | APCH1-Temperature - Rectal | APCH101 | 1 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 38.5-38.9 | C | Y |
| 1 |
| Y | GBR | Non-North America | 0 | 62 | STUDYX | X-200-P0002 | 200 | 2 | 2 | Y | SOC | APCH1-Mean Arterial Pressure | APCH102 | 2 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 110-129 | mmHg | Y |
| 2 |
| Y | GBR | Non-North America | 0 | 63 | STUDYX | X-200-P0002 | 200 | 3 | 3 | Y | SOC | APCH1-Heart Rate | APCH103 | 3 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 70-109 | beats/min | Y |
| 0 |
| Y | GBR | Non-North America | 0 | 64 | STUDYX | X-200-P0002 | 200 | 4 | 4 | Y | SOC | APCH1-Respiratory Rate | APCH104 | 4 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | >=50 | breaths/min | Y |
| 4 |
| Y | GBR | Non-North America | 0 | 65 | STUDYX | X-200-P0002 | 200 | 5 | 5 | Y | SOC | APCH1-Oxygenation: A-aDO2 | APCH105A | 5 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 |
|
|
| Y |
|
|
| GBR | Non-North America | 0 | 66 | STUDYX | X-200-P0002 | 200 | 6 | 6 | Y | SOC | APCH1-Oxygenation: PaO2 | APCH105B | 6 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 61-70 | mmHg | Y |
| 1 |
| Y | GBR | Non-North America | 0 | 67 | STUDYX | X-200-P0002 | 200 | 7 | 7 | Y | SOC | APCH1-Arterial pH | APCH106A | 7 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | <7.15 |
| Y |
| 4 |
| Y | GBR | Non-North America | 0 | 68 | STUDYX | X-200-P0002 | 200 | 8 | 8 | Y | SOC | APCH1-Serum HCO3 | APCH106B | 8 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 |
|
|
| Y |
|
|
| GBR | Non-North America | 0 | 69 | STUDYX | X-200-P0002 | 200 | 9 | 9 | Y | SOC | APCH1-Serum Sodium | APCH107 | 9 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 150-154 | mmol/L | Y |
| 1 |
| Y | GBR | Non-North America | 0 | 70 | STUDYX | X-200-P0002 | 200 | 10 | 10 | Y | SOC | APCH1-Serum Potassium | APCH108 | 10 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 3.5-5.4 | mmol/L | Y |
| 0 |
| Y | GBR | Non-North America | 0 | 71 | STUDYX | X-200-P0002 | 200 | 11 | 11 | Y | SOC | APCH1-Serum Creatinine | APCH109 | 11 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | <0.6 | mg/dL | Y |
| 2 |
| Y | GBR | Non-North America | 0 | 72 | STUDYX | X-200-P0002 | 200 | 12 | 12 | Y | SOC | APCH1-Hematocrit | APCH110 | 12 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 20-29.9 | % | Y |
| 2 |
| Y | GBR | Non-North America | 0 | 73 | STUDYX | X-200-P0002 | 200 | 13 | 13 | Y | SOC | APCH1-White Blood Count | APCH111 | 13 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | >=40 | 10^9/L | Y |
| 4 |
| Y | GBR | Non-North America | 0 | 74 | STUDYX | X-200-P0002 | 200 | 14 | 14 | Y | SOC | APCH1-15 Minus Glasgow Coma Score | APCH112 | 14 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 3 |
| Y |
| 3 |
| Y | GBR | Non-North America | 0 | 75 | STUDYX | X-200-P0002 | 200 | 15 | 15 | Y | SOC | APCH1-A: Total Acute Physiology Score | APCH113 | 15 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 24 |
| Y |
| 24 |
| Y | GBR | Non-North America | 0 | 76 | STUDYX | X-200-P0002 | 200 |
| 16 | Y | SOC | APCH1-A: Total Acute Physiology Score - Analysis | APCH1TPS | 16 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 |
|
| Y |
| 24 |
| Y | GBR | Non-North America | 0 | 77 | STUDYX | X-200-P0002 | 200 | 16 | 17 | Y | SOC | APCH1-B: Age Points | APCH114 | 17 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 65-74 | YEARS | Y |
| 5 |
| Y | GBR | Non-North America | 0 | 78 | STUDYX | X-200-P0002 | 200 | 17 | 18 | Y | SOC | APCH1-C: Chronic Health Points | APCH115 | 18 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | for elective postoperative patients |
| Y |
| 2 |
| Y | GBR | Non-North America | 0 | 79 | STUDYX | X-200-P0002 | 200 | 18 | 19 | Y | SOC | APCH1-Total APACHE II Score | APCH116 | 19 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 | 31 |
| Y |
| 31 |
| Y | GBR | Non-North America | 0 | 80 | STUDYX | X-200-P0002 | 200 |
| 20 | Y | SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | SCREENING | 1 | Baseline | 0 | 2014-08-03 | 03AUG2014 | -2 |
|
| Y |
| 31 |
| Y | GBR | Non-North America | 0 | 81 | STUDYX | X-200-P0002 | 200 |
| 21 | Y | SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II |
|
| Day 15 (Day of Discharge) | 15 |
| 09AUG2014 | 5 |
|
|
|
| 38 | WOC |
| GBR | Non-North America | |
|
|
...
APACHE II Summary Analysis Dataset
...
Dataset wrap |
---|
|
Dataset2 |
---|
Row | STUDYID | USUBJID | SITEID | ASEQ | ITTFL | TRTP | PARAM | PARAMCD | PARAMN | PARCAT1 | VISIT | VISITNUM | AVISIT | AVISITN | ADT | ADY | AVAL | DTYPE | ABLFL | COUNTRY | REGION1 | REGION1N | 20 | STUDYX | X-100-P0001 | 100 | 20 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | SCREENING | 1 | Baseline | 0 | 24JUN2014 | -5 | 22 |
| Y | USA | North America | 1 | 40 | STUDYX | X-100-P0001 | 100 | 40 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 05JUL2014 | 7 | 14 |
|
| USA | North America | 1 | 60 | STUDYX | X-100-P0001 | 100 | 60 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 13JUL2014 | 15 | 6 |
|
| USA | North America | 1 | 80 | STUDYX | X-200-P0002 | 200 | 20 | Y | SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | SCREENING | 1 | Baseline | 0 | 03AUG2014 | -2 | 31 |
| Y | GBR | Non-North America | 0 | 81 | STUDYX | X-200-P0002 | 200 | 21 | Y | SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II |
|
| Day 15 (Day of Discharge) | 15 | 09AUG2014 | 5 | 38 | WOC |
| GBR | Non-North America | |
|
|
7 References
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical Care Medicine 1985; 13(10):818–29.
...